ACADIA Pharmaceuticals In... (ACAD)

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that on August 5, 2025, the Compensation Committee of Acadia's Board of Directors (the “Committee”) granted induc...

ACAD reports encouraging second-quarter results as earnings and revenues beat estimates, driven by year-over-year growth in Nuplazid and Daybue sales.

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD ) Q2 2025 Earnings Conference Call August 6, 2025 4:30 PM ET Company Participants Al Kildani - Corporate Participant Catherine E. Owen Adams - CEO & Director E...

Acadia (ACAD) Q2 Revenue Rises 9%

Acadia Pharmaceuticals (ACAD) came out with quarterly earnings of $0.16 per share, beating the Zacks Consensus Estimate of $0.14 per share. This compares to earnings of $0.2 per share a year ago.

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced its financial results for the second quarter ended June 30, 2025. “Acadia continued to build momentum in the seco...

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the appointment of Scott Cenci as Senior Vice President, Chief Information and Data Officer. In this role, Scott ...

Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Genmab A/S Sponsored ADR (GMAB) and Acadia Pharmaceuticals (ACAD). But which of these two stocks off...

Acadia (ACAD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

ACADIA's valuation is justified by strong revenue growth from NUPLAZID and DAYBUE, with total 2025 revenue guidance of $1B–$1.1B. ACP-101's phase 3 trial for Prader-Willi syndrome is a high-risk catal...